Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics and Safety Following a Single Dose of Emraclidine in Adult Participants With Mild, Moderate, and Severe Hepatic Impairment Compared With Adult Participants With Normal Hepatic Function

NCT05935033 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05935033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05935033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics and Safety Following a Single Dose of Emraclidine in Adult Participants With Mild, Moderate, and Severe Hepatic Impairment Compared With Adult Participants With Normal Hepatic Function
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2023
Completion date
February 21, 2025
Enrollment
38 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment